ProKidney Corp [PROK] stock is trading at $4.54, down -12.36%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PROK shares have gain 612.49% over the last week, with a monthly amount glided 354.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ProKidney Corp [NASDAQ: PROK] stock has seen the most recent analyst activity on June 30, 2025, when BofA Securities downgraded its rating to a Underperform but kept the price target unchanged to $1 for it. On September 10, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $6 on the stock. BofA Securities downgraded its rating to a Neutral. BTIG Research started tracking with a Buy rating for this stock on July 25, 2023, and assigned it a price target of $16. In a note dated December 21, 2022, Jefferies initiated an Buy rating and provided a target price of $15 on this stock.
ProKidney Corp [PROK] stock has fluctuated between $0.46 and $7.13 over the past year. Currently, Wall Street analysts expect the stock to reach $4.67 within the next 12 months. ProKidney Corp [NASDAQ: PROK] shares were valued at $4.54 at the most recent close of the market. An investor can expect a potential return of 2.86% based on the average PROK price forecast.
Analyzing the PROK fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -604.54%, Pretax Profit Margin comes in at -542.68%, and Net Profit Margin reading is -223.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is 0.07 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.20 points at the first support level, and at 3.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.17, and for the 2nd resistance point, it is at 5.79.
Ratios To Look Out For
For context, ProKidney Corp’s Current Ratio is 10.96. In addition, the Quick Ratio stands at 10.96 and the Cash Ratio stands at 2.98. Considering the valuation of this stock, the price to sales ratio is 4286.61.
Transactions by insiders
Recent insider trading involved Weber Darin J., Chief Regulatory Officer, that happened on Jul 08 ’25 when 0.1 million shares were sold. Officer, DARIN J WEBER completed a deal on Jul 08 ’25 to buy 0.1 million shares. Meanwhile, Add’l Rep. Persons-see Ex.99-1 Control Empresarial de Capital bought 0.39 million shares on Apr 22 ’25.
